TuHURA Biosciences (NASDAQ:HURA - Free Report) - Research analysts at Zacks Small Cap issued their FY2027 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a research note issued to investors on Monday, May 19th. Zacks Small Cap analyst J. Vandermosten expects that the company will post earnings per share of ($0.64) for the year.
Separately, HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a report on Friday, May 16th.
Read Our Latest Report on TuHURA Biosciences
TuHURA Biosciences Price Performance
HURA stock traded down $0.18 during midday trading on Wednesday, reaching $2.83. The stock had a trading volume of 110,925 shares, compared to its average volume of 243,796. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $7.93. The business has a fifty day simple moving average of $3.78 and a two-hundred day simple moving average of $4.02.
TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02).
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of HURA. Accent Capital Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter worth approximately $29,000. TT Capital Management LLC acquired a new position in TuHURA Biosciences during the fourth quarter worth $41,000. Jefferies Financial Group Inc. bought a new stake in TuHURA Biosciences during the fourth quarter worth $54,000. Bank of America Corp DE acquired a new stake in TuHURA Biosciences in the fourth quarter valued at $59,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in TuHURA Biosciences in the fourth quarter valued at $61,000. 0.62% of the stock is owned by institutional investors and hedge funds.
TuHURA Biosciences Company Profile
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Articles
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
